Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
22 02 2020
Historique:
received: 25 11 2019
revised: 20 12 2019
accepted: 09 01 2020
pubmed: 3 2 2020
medline: 17 3 2020
entrez: 3 2 2020
Statut: ppublish

Résumé

The WHO Director-General has issued a call for action to eliminate cervical cancer as a public health problem. To help inform global efforts, we modelled potential human papillomavirus (HPV) vaccination and cervical screening scenarios in low-income and lower-middle-income countries (LMICs) to examine the feasibility and timing of elimination at different thresholds, and to estimate the number of cervical cancer cases averted on the path to elimination. The WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), which consists of three independent transmission-dynamic models identified by WHO according to predefined criteria, projected reductions in cervical cancer incidence over time in 78 LMICs for three standardised base-case scenarios: girls-only vaccination; girls-only vaccination and once-lifetime screening; and girls-only vaccination and twice-lifetime screening. Girls were vaccinated at age 9 years (with a catch-up to age 14 years), assuming 90% coverage and 100% lifetime protection against HPV types 16, 18, 31, 33, 45, 52, and 58. Cervical screening involved HPV testing once or twice per lifetime at ages 35 years and 45 years, with uptake increasing from 45% (2023) to 90% (2045 onwards). The elimination thresholds examined were an average age-standardised cervical cancer incidence of four or fewer cases per 100 000 women-years and ten or fewer cases per 100 000 women-years, and an 85% or greater reduction in incidence. Sensitivity analyses were done, varying vaccination and screening strategies and assumptions. We summarised results using the median (range) of model predictions. Girls-only HPV vaccination was predicted to reduce the median age-standardised cervical cancer incidence in LMICs from 19·8 (range 19·4-19·8) to 2·1 (2·0-2·6) cases per 100 000 women-years over the next century (89·4% [86·2-90·1] reduction), and to avert 61·0 million (60·5-63·0) cases during this period. Adding twice-lifetime screening reduced the incidence to 0·7 (0·6-1·6) cases per 100 000 women-years (96·7% [91·3-96·7] reduction) and averted an extra 12·1 million (9·5-13·7) cases. Girls-only vaccination was predicted to result in elimination in 60% (58-65) of LMICs based on the threshold of four or fewer cases per 100 000 women-years, in 99% (89-100) of LMICs based on the threshold of ten or fewer cases per 100 000 women-years, and in 87% (37-99) of LMICs based on the 85% or greater reduction threshold. When adding twice-lifetime screening, 100% (71-100) of LMICs reached elimination for all three thresholds. In regions in which all countries can achieve cervical cancer elimination with girls-only vaccination, elimination could occur between 2059 and 2102, depending on the threshold and region. Introducing twice-lifetime screening accelerated elimination by 11-31 years. Long-term vaccine protection was required for elimination. Predictions were consistent across our three models and suggest that high HPV vaccination coverage of girls can lead to cervical cancer elimination in most LMICs by the end of the century. Screening with high uptake will expedite reductions and will be necessary to eliminate cervical cancer in countries with the highest burden. WHO, UNDP, UN Population Fund, UNICEF-WHO-World Bank Special Program of Research, Development and Research Training in Human Reproduction, Canadian Institute of Health Research, Fonds de recherche du Québec-Santé, Compute Canada, National Health and Medical Research Council Australia Centre for Research Excellence in Cervical Cancer Control.

Sections du résumé

BACKGROUND
The WHO Director-General has issued a call for action to eliminate cervical cancer as a public health problem. To help inform global efforts, we modelled potential human papillomavirus (HPV) vaccination and cervical screening scenarios in low-income and lower-middle-income countries (LMICs) to examine the feasibility and timing of elimination at different thresholds, and to estimate the number of cervical cancer cases averted on the path to elimination.
METHODS
The WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), which consists of three independent transmission-dynamic models identified by WHO according to predefined criteria, projected reductions in cervical cancer incidence over time in 78 LMICs for three standardised base-case scenarios: girls-only vaccination; girls-only vaccination and once-lifetime screening; and girls-only vaccination and twice-lifetime screening. Girls were vaccinated at age 9 years (with a catch-up to age 14 years), assuming 90% coverage and 100% lifetime protection against HPV types 16, 18, 31, 33, 45, 52, and 58. Cervical screening involved HPV testing once or twice per lifetime at ages 35 years and 45 years, with uptake increasing from 45% (2023) to 90% (2045 onwards). The elimination thresholds examined were an average age-standardised cervical cancer incidence of four or fewer cases per 100 000 women-years and ten or fewer cases per 100 000 women-years, and an 85% or greater reduction in incidence. Sensitivity analyses were done, varying vaccination and screening strategies and assumptions. We summarised results using the median (range) of model predictions.
FINDINGS
Girls-only HPV vaccination was predicted to reduce the median age-standardised cervical cancer incidence in LMICs from 19·8 (range 19·4-19·8) to 2·1 (2·0-2·6) cases per 100 000 women-years over the next century (89·4% [86·2-90·1] reduction), and to avert 61·0 million (60·5-63·0) cases during this period. Adding twice-lifetime screening reduced the incidence to 0·7 (0·6-1·6) cases per 100 000 women-years (96·7% [91·3-96·7] reduction) and averted an extra 12·1 million (9·5-13·7) cases. Girls-only vaccination was predicted to result in elimination in 60% (58-65) of LMICs based on the threshold of four or fewer cases per 100 000 women-years, in 99% (89-100) of LMICs based on the threshold of ten or fewer cases per 100 000 women-years, and in 87% (37-99) of LMICs based on the 85% or greater reduction threshold. When adding twice-lifetime screening, 100% (71-100) of LMICs reached elimination for all three thresholds. In regions in which all countries can achieve cervical cancer elimination with girls-only vaccination, elimination could occur between 2059 and 2102, depending on the threshold and region. Introducing twice-lifetime screening accelerated elimination by 11-31 years. Long-term vaccine protection was required for elimination.
INTERPRETATION
Predictions were consistent across our three models and suggest that high HPV vaccination coverage of girls can lead to cervical cancer elimination in most LMICs by the end of the century. Screening with high uptake will expedite reductions and will be necessary to eliminate cervical cancer in countries with the highest burden.
FUNDING
WHO, UNDP, UN Population Fund, UNICEF-WHO-World Bank Special Program of Research, Development and Research Training in Human Reproduction, Canadian Institute of Health Research, Fonds de recherche du Québec-Santé, Compute Canada, National Health and Medical Research Council Australia Centre for Research Excellence in Cervical Cancer Control.

Identifiants

pubmed: 32007141
pii: S0140-6736(20)30068-4
doi: 10.1016/S0140-6736(20)30068-4
pmc: PMC7043009
pii:
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

575-590

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Cost Eff Resour Alloc. 2018 Oct 29;16:38
pubmed: 30450014
Vaccine. 2013 Aug 20;31(37):3863-71
pubmed: 23830974
N Engl J Med. 2007 May 10;356(19):1928-43
pubmed: 17494926
Emerg Infect Dis. 2016 Jan;22(1):18-23
pubmed: 26691673
PLoS Med. 2008 Jun 17;5(6):e132
pubmed: 18563963
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
BMC Med. 2019 Aug 19;17(1):163
pubmed: 31422772
Lancet Public Health. 2017 Feb;2(2):e96-e107
pubmed: 29253402
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):677-86
pubmed: 15767349
Lancet. 2014 Feb 8;383(9916):524-32
pubmed: 24192252
Infect Agent Cancer. 2012 Dec 29;7(1):38
pubmed: 23273245
Am J Epidemiol. 2014 Sep 1;180(5):545-55
pubmed: 25081182
Lancet. 2009 Jul 25;374(9686):301-14
pubmed: 19586656
Med Decis Making. 2018 May;38(4):520-530
pubmed: 29577814
Lancet Public Health. 2016 Nov;1(1):e8-e17
pubmed: 29253379
J Int AIDS Soc. 2018 Jun;21(6):e25110
pubmed: 29873885
Vaccine. 2018 Aug 6;36(32 Pt A):4823-4829
pubmed: 29807710
Int J Cancer. 2017 Jan 15;140(2):440-448
pubmed: 27685757
N Engl J Med. 2009 Apr 2;360(14):1385-94
pubmed: 19339719
N Engl J Med. 2015 Feb 19;372(8):711-23
pubmed: 25693011
CMAJ. 2001 Apr 3;164(7):1017-25
pubmed: 11314432
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Vaccine. 2011 Mar 16;29(13):2487-94
pubmed: 21211586
Vaccine. 2013 Aug 20;31(37):3786-804
pubmed: 23830973
Lancet Oncol. 2019 Mar;20(3):319-321
pubmed: 30795952
Int J Gynaecol Obstet. 2017 Jul;138 Suppl 1:47-56
pubmed: 28691334
Int J Cancer. 2008 Oct 15;123(8):1854-63
pubmed: 18636563
J Natl Cancer Inst. 2012 Nov 21;104(22):1712-23
pubmed: 23104323
Lancet. 2020 Feb 22;395(10224):591-603
pubmed: 32007142
Lancet Glob Health. 2014 Jul;2(7):e406-14
pubmed: 25103394
Lancet Oncol. 2019 Mar;20(3):394-407
pubmed: 30795950
Papillomavirus Res. 2019 Dec;8:100184
pubmed: 31505258
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301
Int J Cancer. 2018 Jul 15;143(2):317-323
pubmed: 29446090
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593

Auteurs

Marc Brisson (M)

Centre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada; Department of Social and Preventive Medicine, Universite Laval, Québec, QC, Canada; MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK. Electronic address: marc.brisson@crchudequebec.ulaval.ca.

Jane J Kim (JJ)

Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Karen Canfell (K)

Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.

Mélanie Drolet (M)

Centre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada.

Guillaume Gingras (G)

Centre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada.

Emily A Burger (EA)

Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Health Management and Health Economics, University of Oslo, Oslo, Norway.

Dave Martin (D)

Centre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada.

Kate T Simms (KT)

Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Élodie Bénard (É)

Centre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada.

Marie-Claude Boily (MC)

Centre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada; Department of Social and Preventive Medicine, Universite Laval, Québec, QC, Canada; MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Stephen Sy (S)

Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Catherine Regan (C)

Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Adam Keane (A)

Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Michael Caruana (M)

Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Diep T N Nguyen (DTN)

Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Megan A Smith (MA)

Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.

Jean-François Laprise (JF)

Centre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada.

Mark Jit (M)

Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene and Tropical Medicine, London, UK; Modelling and Economics Unit, Public Health England, London, UK; School of Public Health, University of Hong Kong, Hong Kong, China.

Michel Alary (M)

Centre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada; Department of Social and Preventive Medicine, Universite Laval, Québec, QC, Canada; Institut national de santé publique du Québec, Québec, QC, Canada.

Freddie Bray (F)

Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.

Elena Fidarova (E)

Department for the Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention, World Health Organization, Geneva, Switzerland.

Fayad Elsheikh (F)

Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Paul J N Bloem (PJN)

Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Nathalie Broutet (N)

Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.

Raymond Hutubessy (R)

Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH